A year after a coronary stent is placed, medicine has long struggled to answer a deceptively simple question: how much protection is enough, and at what cost? A large Korean trial presented this summer at the European Society of Cardiology Congress offers not a universal answer, but something more honest — evidence that the right choice depends on who the patient is, how many risks they carry, and how those risks compound one another. In high-risk patients, continuing aspirin alongside clopidogrel beyond the first year reduced heart attacks and deaths, even as it raised the likelihood of bleed